Curaleaf buys Polish medical marijuana company Can4Med

Curaleaf International, a division of Curaleaf Holdings (OTCQX: CURLF) (TSX:CURA) is buying Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland.

Curaleaf had noted in its last MD&A that it planned to continue investing internationally, to expand its vertically integrated presence in major medical-use markets across Europe and best position itself to benefit from the potential legalization of adult-use across the European continent. Curaleaf did not tell investors how much it paid for the company and whether the acquisition was paid for in cash or stocks.

“This acquisition represents a significant step forward for Curaleaf International. Poland’s medical cannabis market is expanding rapidly, and our partnership with Can4Med allows us to better serve patients while driving growth across Europe,” said Matt Darin, CEO of Curaleaf.

In Germany, Curaleaf supplies medical cannabis on a wholesale basis to pharmacies and to other distributors. It also supplies medical cannabis to private importers of its products. All international, non-cannabis revenues are derived from wholesale transactions in Spain, the U.K., Switzerland and Germany.

According to the Curaleaf statement, Poland boasts one of Europe’s largest patient populations seeking medical cannabis. By joining forces with Can4Med, Curaleaf International gains a strong foothold in this dynamic market, allowing it to serve patients more effectively and expand its product offerings.

“We are thrilled that Can4Med, a pioneering force in Poland’s cannabis market, has joined forces with Curaleaf, the global leader in cannabis. This acquisition marks a significant milestone in our journey, ensuring an unparalleled supply chain that positions us to meet and exceed the demands of the entire Polish market. Partnering with Curaleaf not only reinforces our commitment to quality and accessibility but also signifies a new era of growth and possibilities for both companies and our customers,” said Maximilian Weinberg, founder of Can4Med.

Curaleaf also noted that the Polish Pharmaceutical Chamber estimates that the potential number of medical cannabis users could reach 300,000, while the number of legal cannabis users (both medical and CBD) is expected to reach 1.3 million by 2026.

The company also stated in its MD&A released in November 2023 that it has presented 19 research abstracts across both the International Cannabinoid Research Society 2023 conferences and the British Pain Society National Meeting, of which 14 contained outcomes from the registry. It has a total of 11 studies submitted for peer review at present, with the majority of these expected to be published between November 2023 and early 2024.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.